Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)

PHASE3TerminatedINTERVENTIONAL
Enrollment

1,030

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

May 31, 2011

Study Completion Date

June 30, 2011

Conditions
Osteoarthritis
Interventions
DRUG

Oral Salmon Calcitonin

0.8mg SMC021, twice daily

DRUG

Oral Salmon Calcitonin (Placebo)

0.8mg Placebo, twice daily

Trial Locations (18)

1200

Hospital Universitaire St. Luc, UCL 5390, Brussels

2750

CCBR Ballerup, Ballerup Municipality

7100

CCBR Vejle, Vejle

9000

CCBR Aalborg, Aalborg

27599

Thurston Arthritis Research Center, Chapel Hill

28046

Hospital Universitario de la Paz, Madrid

35406

Achieve Clinical Research, LLC, Tuscaloosa

44122

Rheumatology Clinical Research Unit, Beachwood

53002

CCBR Czech, Pardubice

60611

Northwestern Center for Clinical Research, Chicago

63376

Midwest Pharmaceutical Research, City of Saint Peters

95817

Center for Healthy Aging, Sacramento

G1W 4R4

Centre de Rhumatologie St-Louis, Sainte-Foy (Québec)

Unknown

CCBR Hong Kong, Hong Kong

15-461

Centrum Osteoporozy i Chorób Kostno Stawowych, ul. Waryńskiego 6/2, Bialystok

04703

CCBR Poland, Warsaw

030463

CCBR Romania, Bucharest

TN 39 4SP

Little Common Surgery, Bexhill-on-Sea

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Nordic Bioscience A/S

INDUSTRY

NCT00704847 - Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study) | Biotech Hunter | Biotech Hunter